Você está usando um navegador não compatível.
Alguns recursos deste site podem não funcionar corretamente. Para uma experiência de usuário ideal, visualize este site no Chrome, Firefox, Safari ou Edge.

Publicações

Congressos e publicações/Publicações

Publicações mais recentes

Imagem de banner com moléculas azuis e vermelhas Para acessar esses artigos, pode ser necessário que você e/ou sua instituição tenham a assinatura dos periódicos.

BGB-10188

A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon

2024

BGB-A1217

Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody ociperlimab

2024

An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models.

2022

BGB-A333

Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

2023

BGB-A445

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

2025

BGB-DXP593

SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial

2023

Lifirafenib

Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase Inhibitor, in patients with solid tumors

2020

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors

2020

Obinutuzumab

ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma

2023

View publication in Plain Language

Ociperlimab

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

2023

Pamiparib

Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

2024

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

2023

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

2022

Human mass balance and metabolite profiling of [14-C]-pamiparib, a poly (ADP-Ribose) polymerase inhibitor, in patients with advanced cancer

2021

Pamiparib monotherapy for patients with germline BRCA1/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study

2021

Phase 1a/1b dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

2021

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors; an open-label, parallel-group phase 1 study

2021

Discovery of pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development

2020

Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer

2020

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

2020

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1A/B trial

2019

Load More

Sitravatinib

SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma

2024

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

2024

Sonrotoclax

Biotransformation and disposition of C14-labeled sonrotoclax ([14C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome

2025

Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2

2024

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy

2024

Tislelizumab

First-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer: three-year follow-up of the phase 3 RATIONALE-309 randomized clinical trial

2026

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

2025

Alternative dosing regimens of tislelizumab using a pharmacometrics model-based approach

2025

Anti-LAG-3 antibody LBL-007 plus tislelizumab and chemotherapy as first-line therapy for advanced nasopharyngeal carcinoma: a multicenter phase 2 trial

2025

Clinical pharmacology overview of tislelizumab in patients with advanced tumors with a focus on racial impact

2025

Comparative effectiveness and safety of tislelizumab versus other anti–PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non–small cell lung cancer: Systematic literature review and network meta-analysis

2025

Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis

2025

Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with tislelizumab

2025

First-line tislelizumab plus chemotherapy for advanced gastric cancer with programmed death-ligand 1 expression ≥ 1%: a retrospective analysis of RATIONALE-305

2025

First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression ≥ 1%: a retrospective analysis of RATIONALE-306

2025

First‑line tislelizumab plus chemotherapy in advanced non‑squamous non‑small cell lung cancer: PD‑L1≥50% subgroup analysis from the RATIONALE‑304 trial

2025

Immunogenicity of tislelizumab: clinical summary of ADA incidence and feasibility of assessing the suitability of validation cut points using statistical methods

2025

Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers

2025

NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: a biomarker analysis from the randomized, phase III, RATIONALE-302 trial

2025

Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial

2025

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study

2025

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

2024

Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer

2024

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial

2024

SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma

2024

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

2024

Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302

2024

The concomitant of non-classical stereotactic body radiotherapy with tislelizumab based on multidisciplinary modalities for leiomyosarcoma: A case report

2024

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

2024

Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)

2024

Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial

2024

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

2024

Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small cell lung cancer (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial

2024

Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

2023

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

2023

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors

2023

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial

2023

Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer

2023

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

2023

The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer

2023

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)

2023

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

2023

Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a Phase 3 randomized clinical trial

2023

Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia

2023

Examining the impact of tislelizumab added to chemotherapy on health-related quality-of-life outcomes in previously untreated patients with nonsquamous non–small cell lung cancer

2022

HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma

2022

Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

2022

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

2022

Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (rationale-208): a multicenter, non-randomized, open-label, phase 2 trial

2022

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study

2022

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

2022

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial

2022

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma

2021

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma

2021

The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: results from a phase 3 randomized clinical trial

2021

Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis

2021

Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer (RATIONALE 304): a randomized phase 3 trial

2021

Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial

2021

Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage

2021

A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients

2020

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

2020

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

2020

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

2020

Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma

2020

A human peripheral blood mononuclear cell (PBMC) engrafted humanized xenograft model for translational immuno-oncology (I-O) research

2019

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1A/B trial

2019

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

2019

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

2019

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

2018

Load More

ZW25

HERIZON-GEA-01: zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma

2022

Zanubrutinib

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings

2025

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

2025

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

2025

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

2025

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

2025

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with R/R MCL: an extended follow-up analysis

2025

Indirect comparisons of the efficacy and safety of zanubrutinib versus venetoclax plus obinutuzumab in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

2025

Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia

2025

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia

2025

Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

2025

Relative bioavailability, food effect, and bioequivalence studies to assess a new zanubrutinib 160-mg tablet: results from 2 phase 1 studies in healthy volunteers

2025

Zanubrutinib and venetoclax for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma with and without del(17p)/TP53 mutation: SEQUOIA Arm D results

2025

Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL

2025

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: updated results

2025

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

2025

A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon

2024

Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia

2024

Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib

2024

Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database

2024

Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea

2024

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

2024

Health-related quality of life in patients with Waldenström macroglobulinemia: Results from the ASPEN trial

2024

Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE

2024

Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma

2024

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial

2024

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström Macroglobulinemia

2024

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

2024

Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset

2024

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

2024

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

2024

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

2024

Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2

2024

Zanubrutinib versus bendamustine and rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA

2024

A phase 1, open-label, fixed-sequence, drug-drug interaction study of zanubrutinib with rifabutin in healthy volunteers

2023

Health-related quality of life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab

2023

Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial

2023

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

2023

Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: an updated pooled analysis

2023

Molecular associations of response to the new generation BTK inhibitor zanubrutinib in marginal zone lymphoma

2023

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

2023

ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma

2023

View publication in Plain Language
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

2023

Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis

2023

Zanubrutinib in patients with relapsed/refractory hairy cell leukemia

2023

Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: an expanded-access study of 50 patients in the United States

2023

Zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study

2023

Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia

2023

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

2022

A phase II study of zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma

2022

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies

2022

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

2022

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

2022

Zanubrutinib monotherapy for naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: a pooled analysis of three studies

2022

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

2022

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

2022

Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia

2022

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

2022

Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial

2022

A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory Waldenström macroglobulinemia

2021

Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib

2021

Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator

2021

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

2021

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

2021

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

2021

The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase Inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma

2021

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

2021

Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study

2021

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

2021

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

2021

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

2020

A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

2020

A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study

2020

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

2020

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-GP, and BCRP

2020

No QTc prolongation with zanubrutinib: results of concentration-QTc analysis from a thorough QT study in healthy subjects

2020

Nonclinical safety assessment of zanubrutinib: a novel irreversible BTK inhibitor

2020

Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B-cell malignancies

2020

Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase

2020

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

2020

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

2020

Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial

2020

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up

2020

Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion

2020

Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase

2019

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton’s tyrosine kinase inhibitor) in Asian and non‑Asian healthy subjects

2019

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

2019

A head-to-head phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia

2018

Load More
Volte para Congressos e publicações

Uma parte do conteúdo está disponível apenas em inglês.

Powered by Translations.com GlobalLink Web Software